Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, October 6, 2022
AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK
Wednesday, October 5, 2022
AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
Friday, September 23, 2022
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
Wednesday, January 12, 2022
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: